Summarized by Masters of Longevity from PR Newswire.
Clinical Phase II data for a Nectin‑4-targeting antibody‑drug conjugate will be presented, focusing on patients with prior ADC therapy for triple‑negative breast cancer.
Key Takeaways
- Among 60 Topo I ADC‑pretreated TNBC patients, the objective response rate was 30.0%.
- Median progression‑free survival in this cohort was 3.7 months and median duration of response was 8.7 months.
- No new safety signals were observed during the reported follow‑up period.
